Indivior (LON:INDV)‘s stock had its “buy” rating reiterated by stock analysts at Numis Securities in a research note issued on Thursday. They presently have a GBX 640 ($8.84) target price on the specialty pharmaceutical company’s stock. Numis Securities’ price target suggests a potential upside of 67.10% from the company’s current price.
A number of other brokerages have also issued reports on INDV. Morgan Stanley reaffirmed an “equal weight” rating and set a GBX 410 ($5.66) target price on shares of Indivior in a research report on Friday, December 1st. Citigroup raised shares of Indivior to a “buy” rating and boosted their target price for the stock from GBX 280 ($3.87) to GBX 490 ($6.77) in a research report on Wednesday, November 8th. Jefferies Group boosted their target price on shares of Indivior from GBX 358 ($4.95) to GBX 472 ($6.52) and gave the stock a “buy” rating in a research report on Thursday, November 9th. Finally, Royal Bank of Canada boosted their target price on shares of Indivior from GBX 500 ($6.91) to GBX 540 ($7.46) and gave the stock an “outperform” rating in a research report on Friday, January 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of GBX 482.14 ($6.66).
Indivior (LON INDV) opened at GBX 383 ($5.29) on Thursday. Indivior has a 52-week low of GBX 246.50 ($3.41) and a 52-week high of GBX 436.60 ($6.03). The stock has a market cap of $2,740.00 and a price-to-earnings ratio of 7,660.00.
COPYRIGHT VIOLATION WARNING: “Indivior (INDV) Stock Rating Reaffirmed by Numis Securities” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/17/indivior-indv-stock-rating-reaffirmed-by-numis-securities-2.html.
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.